Crowdonomics
This isn’t Monogram Orthopaedics’s most recent raise. Reg A+ · Equity · Nov 2022 (Closed) is more current.View latest round
Monogram Orthopaedics

Reg CF · Preferred Stock · Jul 2022

ClosedReg CFPreferred Equity
via DealMaker · last checked Sep 28, 2026
Raised
$0 / $5M max
0% of ceiling
Investors
—
—
Estimated pre-money
$129.4M
—

Financials disclosed in this offering

FY2020–FY2021 · hover for source
$0
−$9.1M
FY2020
$628K
−$11.8M
FY2021
RevenueNet income
Metric
FY2020 audited
FY2021 audited
Income statement
Revenue
$0
$628,246
Cost of goods sold
$0
$458,675
Gross margin
—
27%
Net income
-$9,068,006
-$11,814,968
Taxes paid
$0
$0
Balance sheet
Cash
$5,586,748
$5,535,710
Accounts receivable
$0
$0
Total assets
$8,115,888
$8,715,366
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$3,126,456
$5,212,208
Other
Headcount
—
23

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Est. pre-money$129.4M
Price / share$10.01
Price / share today$5.005
Shares offered9,991

Estimated, not stated: $10.01 × 12,930,155 as-converted securities outstanding as of Jun 30, 2022 (Form 1-A/A filed Feb 23, 2023, p. 1).

$10.01 as sold; $5.005 after the Nov 2022 split (2:1) (Form 1-A, p. 1).

Offering details

Target$100,000
Max$5,000,000
Min investment—
OpenedJul 14, 2022
DeadlineOct 31, 2022
ClosedOct 31, 2022
Days active109

Links & provenance

Source: SEC EDGAR
0001104659-22-079911
Last synced Sep 28, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.